Gilead Settles Teva HIV Drug Patent Suit to Avoid Trial

Teva Pharmaceuticals and Gilead Sciences Inc. agreed to settle a patent dispute over Viread, a treatment for HIV infection and chronic Hepatitis B, avoiding a trial that was scheduled to start today, Gilead said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.